Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
330 results about "Muscarinics receptors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Muscarinic receptor antagonists
Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Neurogenesis by muscarinic receptor modulation
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
Owner:BRAINCELLS INC
Biphenyl compounds useful as muscarinic receptor antagonists
ActiveUS7288657B2Long duration of actionImprove performanceNervous disorderOrganic chemistryDiseaseCombinatorial chemistry
This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Biphenyl compounds useful as muscarinic receptor antagonists
ActiveUS7262205B2Long duration of actionImprove performanceBiocideOrganic chemistryCombinatorial chemistryAntagonist
This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Combinations comprising antimuscarinic agents and beta-adrenergic agonists
Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.
Owner:GRAS ESCARDO JORDI +3
Biphenyl compounds useful as muscarinic receptor antagonists
ActiveUS20050203083A1Improve performanceReduce systemic side effectsBiocideOrganic chemistryCombinatorial chemistryAntagonist
This invention provides compounds of formula I: wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
New uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
ActiveUS20080114014A1Maximizing beneficial effectMaximize the effectBiocideNervous disorderSolubilityFecal incontinence
A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and / or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.
Owner:QAAM PHARMA LLC
Biphenyl compounds useful as muscarinic receptor antagonists
ActiveUS7560469B2Improve performanceReduce systemic side effectsBiocideOrganic chemistryCombinatorial chemistryReceptor antagonist
This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, s, t, Ar1, R1, R2, R3, R4, R6, R7, R8, and W are as defined in the specification. The compounds of formula I are mescaline receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Pharmaceutical combination
ActiveUS20130172277A1High potencyImprove efficacyBiocidePharmaceutical delivery mechanismMuscarinic antagonistAdrenergic
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
Owner:B3AR THERAPEUTICS INC
Biphenyl compounds useful as muscarinic receptor antagonists
ActiveUS7569588B2Long duration of actionImprove performanceBiocideOrganic chemistryStereochemistryBiphenyl compound
This invention provides compounds of formula I:wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Modulators of muscarinic receptors
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
Owner:VERTEX PHARMA INC
Methods and compositions for protecting and treating muscarinic receptors through administration of at least one protective agent
InactiveUS20060009414A1Increase awarenessTreat or prevent brain deterioration or cognitive and memory loss associatedBiocideNervous disorderGastroenterologyProtective Agents
Methods and compositions for protecting muscarinic receptor(s) in a subject by administering at least one protective agent alone, in combination with other protective agents, or in combination with at least one neurologic agent.
Owner:HEALTHPARTNERS RESEACH FOUND
Muscarinic M1 receptor agonists for pain management
InactiveUS20050130961A1Alleviate acute painRelieve symptomsBiocideNervous disorderAgonistNeuropathic pain
Disclosed herein are compounds and methods for treating chronic neuropathic pain. It has been discovered that compounds that selectively interact with a muscarinic receptor subtype are effective in treating neuropathic pain. Specifically, compounds that selectively interact with the M1 muscarinic receptor subtype may be used.
Owner:ACADIA PHARMA INC
Combinations comprising antimuscarinic agents and beta-adrenergic agonists
Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.
Owner:ALMIRALL
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
InactiveUS20050176664A1Improve bioavailabilityMinimize the possibilityCompounds screening/testingNervous disorderMuscarinic receptor siteCholinergic receptor muscarinic 3
This invention relates to compounds, compositions, and methods useful for modulating cholinergic muscarinic receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of cholinergic muscarinic receptor gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of cholinergic muscarinic receptor genes, such as M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3).
Owner:SIRNA THERAPEUTICS INC
Substituted 4-amino-1-benzylpiperidine compounds
ActiveUS20050026954A1Potent inhibitorSurprising and unexpected selectivityBiocideOrganic chemistryMedicine1-benzylpiperidine
This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Modulators of muscarinic receptors
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
Owner:VERTEX PHARMA INC
Oral liquid tolterodine composition
A pharmaceutical composition in a form of an orally deliverable liquid comprises water having in solution therein a pharmaceutically acceptable water-soluble salt of a tolterodine related compound at a therapeutically effective concentration in the composition. The composition has a pH of about 2 to about 6 and further comprises a sweetening agent and an antimicrobial agent at a concentration that is antimicrobially effective at the pH of the composition. The composition is useful for treating a muscarinic receptor mediated disorder, more particularly overactive bladder, in a subject by orally administering to the subject a therapeutically effective amount of the composition.
Owner:PHARMACIA CORP
Therapeutic carbamates
InactiveUS7238709B2Reduce dose requiredLong duration of actionBiocideSenses disorderCarbamateMedicinal chemistry
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases
ActiveUS20130172398A1Prevents or substantially ameliorates the undesired side effects of acetyl-cholinesteraseMaximize the effectBiocideAmine active ingredientsDementia with Lewy bodiesPsychiatry
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
Owner:QAAM PHARMA LLC
Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions
InactiveUS20060009413A1Increase awarenessTreat or prevent brain deterioration or cognitive and memory loss associatedBiocideNervous disorderMedicineDisease cause
Methods and compositions for protecting muscarinic receptor(s) in a subject from at least one carcinogenic or toxic metal by administration of a pyrophosphate analog. Methods and compositions for preventing at least one disease induced or caused by metals compromising the function of muscarinic receptors in a subject by administration of a pyrophosphate analog. Methods and compositions for reducing toxic action of metal ions and for reducing poisoning by metals by administering a pyrophosphate analog.
Owner:HEALTHPARTNERS RESEACH FOUND
Tetrahydroquinoline analogues as muscarinic agonists
InactiveUS20050209226A1Increased intraocular pressureSenses disorderNervous disorderTreatment useMuscarinics
The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Owner:ACADIA PHARMA INC
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
InactiveUS20110020423A1Eliminate side effectsIncrease the maximum tolerated doseBiocideNervous disorderActivation methodDisease
Owner:PURETECH VENTURES +1
Spiro compounds as modulators of muscarinic receptors
Owner:VERTEX PHARMA INC
Methods and compositions for protecting and treating at least one muscarinic receptor from dysfunction not resulting from oxidative stress, toxic actions of metals or infectious agents by administering a pyrophosphate analog
Methods and compositions for protecting and treating a muscarinic receptor in a subject in need thereof from dysfunction not resulting from oxidative stress, toxic actions of metals or metal ions, or infectious agents by administering a pyrophosphate analog.
Owner:HEALTHPARTNERS RESEACH FOUND
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
InactiveUS20050014172A1Improve bioavailabilityMinimize the possibilityCompounds screening/testingNervous disorderMuscarinic cholinergicFhit gene
The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of cholinergic muscarinic receptor genes, or other genes involved in pathways of cholinergic muscarinic receptor gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3).
Owner:SIRNA THERAPEUTICS INC
Combination of pilocarpin and methimazol for treating Charcot-Marietooth disease and related disorders
The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.
Owner:PHARNEXT
Muscarinic receptor agonists
InactiveUS6911477B2Increase neurotransmissionSimple processBiocideOrganic chemistryDiseaseMuscarinic agonist
This invention relates to a novel class of partial or full muscarinic receptor agonists intermediates for their preparation, and pharmaceutical compositions and methods of use for the treatment or prevention of diseases the treatment or prevention of which is mediated by muscarinic receptor agonism.
Owner:PFIZER INC
Biphenyl derivatives
This invention provides biphenyl derivatives of formula I: wherein R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Pharmaceutical combinations
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
Owner:B3AR THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com